Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody

en-cphi.cnMarch 21, 2019

Tag: Innovent Biologics , monoclonal antibody , trial

PharmaSources Customer Service